8-K: KORU Medical Systems Announces Record Q1 2025 Financial Results and Raises 2025 Revenue Guidance

KORU Medical Systems reports strong Q1 2025 results with an 18% revenue increase and raises its full-year revenue guidance.

Summary

• KORU Medical Systems announced its financial results for the first quarter ended March 31, 2025.
• Net revenues for Q1 2025 reached $9.6 million, an 18% increase compared to the prior year period.
• Core business net revenues (domestic and international) grew by 21% to $9.4 million.
• Gross profit increased by 19% to $6.0 million, with a gross margin of 62.8%, a 50-basis point improvement.
• The company's cash balance at the end of the quarter was $8.7 million, with a quarterly cash usage of $0.8 million.
• KORU Medical plans to submit for FDA 510(k) clearance for two commercialized drugs with the Freedom Infusion System in 2025.
• Full-year 2025 revenue guidance has been raised to $38.5 $39.5 million from the previous range of $38.0 $39.0 million.
• The company is reiterating its full-year gross margin guidance of 61% 63% and expects positive cash flow from operations for the full year 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong Q1 results, increased revenue guidance, and expectations for positive cash flow. While there are some challenges mentioned, the overall tone is optimistic.

Positives

• Net revenues increased by 17.5% to $9.6 million for the three months ended March 31, 2025.
• Domestic core revenues increased by 16.4% due to higher pump and consumable volumes.
• International core revenues increased by 35.6% due to geographical expansion and a tender win.
• Gross profit increased by 18.5% to $6.0 million.
• Net loss decreased by $0.8 million compared to the prior year period.
• Adjusted EBITDA improved from ($0.9) million to ($0.2) million.
• The company ended the quarter with a cash balance of $8.7 million.

Negatives

• Pharma services and clinical trials net revenues decreased by 38.6% due to lower clinical trial revenue.
• Total operating expenses increased by $0.2 million, driven by compensation-related expenses and legal fees.
• The company experienced a net loss of $1.166 million for the quarter.
• Adjusted EBITDA was still negative at ($0.2) million.

Risks

• The company acknowledges a challenging macroeconomic backdrop.
• Uncertainties associated with SCIg market growth, prefilled syringe penetration, plasma supply, clinical trial activity and success, approval and commercialization of new drug indications, the shift to increased healthcare delivery in the home, new patient diagnoses, customer ordering patterns, global health crises, innovation and competition, labor and supply price increases, inflationary impacts, labor supply, and tariffs could impact future results.

Future Outlook

KORU Medical is raising its full-year 2025 net revenue guidance to $38.5 $39.5 million and reiterating its full-year gross margin guidance of 61% 63% and positive cash flow from operations.

Management Comments

• Linda Tharby, President and CEO of KORU Medical, stated that the company is off to a strong start this year, with over 20% growth in their core business.
• She also mentioned that the company is advancing its novel therapies pipeline and plans to submit two previously commercialized drugs for 510(k) clearance with the Freedom Infusion system by year-end.
• Tharby expressed confidence in the company's ability to deliver through the remainder of the year, despite a challenging macroeconomic backdrop.

Industry Context

KORU Medical operates in the medical technology sector, specifically focusing on subcutaneous infusion solutions. The company's growth is driven by factors such as new patient starts, market share gains, and geographical expansion. The increasing shift towards healthcare delivery in the home also benefits KORU Medical's business.

Comparison to Industry Standards

• It's difficult to provide a precise comparison without knowing KORU Medical's direct competitors' Q1 2025 results.
• However, medical device companies like Insulet (PODD) and Tandem Diabetes Care (TNDM), which focus on drug delivery systems, could be considered peers.
• Investors would typically compare KORU Medical's revenue growth, gross margins, and profitability metrics against these companies to assess its relative performance.
• For example, if Insulet and Tandem are growing at similar rates or have higher gross margins, it might suggest that KORU Medical is underperforming relative to its peers.

Legal Proceedings

• The company incurred legal fees with respect to a claim filed by the Company alleging patent infringement.

Stakeholder Impact

• Shareholders will likely react positively to the increased revenue guidance and improved financial performance.
• Employees may be encouraged by the company's growth and future prospects.
• Customers will benefit from the company's continued innovation and development of patient-centric solutions.
• Suppliers may see increased demand for their products and services as the company grows.

Next Steps

• The company will host a conference call and webcast on May 7, 2025, to discuss the results and provide a corporate update.
• KORU Medical plans to submit for FDA 510(k) clearance for two commercialized drugs with the Freedom Infusion System in 2025.

Key Dates

Keywords

KORU Medical, financial results, revenue guidance, infusion systems, medical technology, adjusted EBITDA, net revenues, gross margin, 510(k) clearance